The world’s best-selling drug class doesn’t have a demand problem. It has a GLP-1 supply chain problem — and the companies that solve it first will own the next decade of pharma.

Pharmaceutical giants are no longer competing only on molecules. They are, in addition, competing on factories, geography, and geopolitics. The race to secure production of GLP-1 receptor agonists — a class of drugs used to treat obesity and type 2 diabetes — has triggered one of the largest manufacturing buildouts in the history of the industry. Eli Lilly alone is spending more than $15 billion globally to expand its production network. Meanwhile, rivals are snapping up contract manufacturers and building new plants from Ireland to South Korea.

The stakes are enormous. The global GLP-1 market is projected to reach between $150 billion and $200 billion by 2030. In the United States alone, roughly 30 million patients could be on these drugs by the end of the decade. That kind of demand doesn’t just require good science — it requires an industrial infrastructure that barely exists yet.

Why the GLP-1 Supply Chain Is So Hard to Build

GLP-1 drugs, short for glucagon-like peptide-1 receptor agonists, work by mimicking a hormone that regulates blood sugar and appetite. Most current treatments — such as Novo Nordisk’s Ozempic and Wegovy, or Lilly’s Mounjaro and Zepbound — are injectable. However, the peptide-based active pharmaceutical ingredients (APIs) behind these drugs are notoriously difficult to synthesize. The fill-and-finish process, where the drug is loaded into injection pens, creates further bottlenecks.

Manufacturing complexity is only part of the challenge. Geopolitical risk is the other. Governments around the world are pushing for domestic drug production. The United States has floated tariffs on pharmaceutical imports. Countries across Asia are demanding local supply. As a result, a company that relies on a single country for production is now seen as strategically exposed.

The shift to oral GLP-1 pills adds another layer of urgency. Pills require entirely different manufacturing lines — high-volume solid-dose facilities rather than sterile injectable suites. Companies that don’t build this capacity now risk missing the next wave entirely.

Lilly’s $1.5 Billion Stockpile and the Oral GLP-1 Gamble

Eli Lilly has accumulated approximately $1.5 billion worth of inventory — around 2.16 trillion Korean won — ahead of the anticipated broad launch of orforglipron, its once-daily oral GLP-1 candidate. In the United States, the drug has already received FDA approval under the brand name Foundayo. In China, it is currently under regulatory review.

The stockpile is a deliberate hedge. Lilly is, in particular, trying to avoid the supply embarrassments that plagued the injectable GLP-1 market in its early years, when shortages forced patients off medication mid-treatment. For investors, a pre-built inventory buffer signals that Lilly is treating orforglipron not as a test product but as a blockbuster launch.

Oral drugs are a category-expanding move. Patients who refuse injections — a significant population — become accessible. That expands the addressable market well beyond current estimates.

The Asia Pivot: China and Japan at the Center

Lilly’s geographic strategy is becoming clear. Over the next decade, the company will invest $3 billion — roughly 4.32 trillion won — in China, localizing oral solid-dose production and supply chain operations at its Suzhou facility. By 2028, it will also inject approximately 20 billion yen (around 181.4 billion won) into its Kobe, Japan plant to expand manufacturing and logistics capacity.

Edyta Hamzic, a healthcare analyst at GlobalData, framed the logic plainly. “Lilly’s recent investments show that the GLP-1 market is no longer shaped by demand alone,” she noted. “Companies are building geographically distributed manufacturing networks to serve local markets, manage policy pressure, and protect against disruptions that could affect access to critical medicines.”

For China specifically, the strategic rationale goes beyond logistics. Orforglipron faces limited domestic competition in the Chinese oral GLP-1 segment. Therefore, building local production capacity now is not just about cost efficiency — it is about market timing. A locally manufactured drug faces fewer import barriers, shorter lead times, and stronger relationships with regulators and health systems.

Asia is not a fallback option for Lilly. It is the primary growth theater.

Korea’s Role: From CDMO Hub to Innovation Gateway

South Korea’s position in the GLP-1 supply chain story is evolving fast. Samsung Biologics — Korea’s dominant contract development and manufacturing organization, or CDMO — is partnering with Lilly to build the “Lilly Gateway Labs” (LGL) at the Songdo Bio Campus II in Incheon. The facility is expected to open by 2027.

CDMOs like Samsung Biologics function as outsourced production partners for global drug companies. Korea has built a formidable CDMO cluster in Incheon’s Songdo district, which functions as a dedicated biotech industrial zone. However, the Lilly Gateway Labs project signals something beyond contract manufacturing.

John Rim, CEO of Samsung Biologics, described the collaboration as a platform for “global open innovation,” designed to bring promising scientific discoveries through drug development and into global commercialization. The facility will host up to 30 domestic and international biotech startups, providing research and development support. Furthermore, it follows similar Lilly innovation hubs already established in the United States and China — placing Korea in genuinely elite company.

For Korea, this matters at a strategic level. The country has spent years building its reputation as a reliable CDMO base. The Gateway Labs partnership, by contrast, positions Korea as a node in early-stage drug discovery — not just a factory. That distinction carries significant implications for talent attraction, government policy, and long-term investment flows into the Korean biotech ecosystem.

Korea is no longer just assembling drugs. It is helping design them.

Competitors Are Not Standing Still

Novo Nordisk, Lilly’s closest rival in the GLP-1 space, is expanding its Athlone, Ireland facility to produce oral semaglutide — the active ingredient in Rybelsus — for markets outside the United States. The Danish company also made one of the boldest supply chain moves in recent pharma history: acquiring Catalent, a major global CDMO, for $16.5 billion. That deal gave Novo Nordisk direct control over several key manufacturing sites, effectively internalizing capacity that competitors must now secure elsewhere.

German packaging specialist Enova has expanded its high-speed tube packaging lines to handle increased GLP-1 pill volumes. These kinds of downstream investments — often invisible to the public — are, nevertheless, essential links in the chain between a drug’s synthesis and its arrival at a pharmacy.

The competitive dynamic is shifting. First-mover advantages in supply chain now rival first-mover advantages in clinical data.

What the Outlook Means for Investors

The near-term picture involves continued supply tightness. However, the window between 2027 and 2029 is expected to be transformative. By that point, the major capacity investments now underway — including Lilly’s Asian facilities, Novo’s expanded European network, and Korea’s CDMO buildout — should come online. As a result, market competition will intensify sharply on both price and access.

The therapeutic frontier is also expanding. GLP-1 drugs are showing promise beyond obesity and diabetes — in cardiovascular disease, sleep apnea, and early-stage Alzheimer’s research. Each new indication expands the potential patient population and, therefore, the demand that manufacturers must be ready to meet.

For investors tracking this space, the key variables are no longer just pipeline data and clinical trial results. Factory locations, CDMO contracts, and regulatory approvals in China and Japan now carry equal weight. Companies with distributed, locally embedded manufacturing networks will be better positioned to weather the policy turbulence ahead.

In the GLP-1 era, supply chain is strategy. And right now, Lilly is playing that game more aggressively than almost anyone else.